Aligos Therapeutics Inc (ALGS)
19.46
+0.01
(+0.05%)
USD |
NASDAQ |
Nov 14, 16:00
19.40
-0.06
(-0.31%)
After-Hours: 20:00
Aligos Therapeutics Enterprise Value: -5.137M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | -5.137M |
| November 12, 2024 | -10.88M |
| November 11, 2024 | -24.73M |
| November 08, 2024 | -38.36M |
| November 07, 2024 | -39.33M |
| November 06, 2024 | -41.38M |
| November 05, 2024 | -39.65M |
| November 04, 2024 | -40.91M |
| November 01, 2024 | -43.17M |
| October 31, 2024 | -42.41M |
| October 30, 2024 | -42.44M |
| October 29, 2024 | -43.80M |
| October 28, 2024 | -45.43M |
| October 25, 2024 | -46.99M |
| October 24, 2024 | -44.90M |
| October 23, 2024 | -50.95M |
| October 22, 2024 | -50.52M |
| October 21, 2024 | -50.68M |
| October 18, 2024 | -50.82M |
| October 17, 2024 | -50.95M |
| October 16, 2024 | -50.38M |
| October 15, 2024 | -50.75M |
| October 14, 2024 | -50.88M |
| October 11, 2024 | -49.59M |
| October 10, 2024 | -52.01M |
| Date | Value |
|---|---|
| October 09, 2024 | -49.12M |
| October 08, 2024 | -50.58M |
| October 07, 2024 | -49.99M |
| October 04, 2024 | -47.79M |
| October 03, 2024 | -47.69M |
| October 02, 2024 | -46.36M |
| October 01, 2024 | -46.26M |
| September 30, 2024 | -46.13M |
| September 27, 2024 | -68.84M |
| September 26, 2024 | -68.90M |
| September 25, 2024 | -68.26M |
| September 24, 2024 | -68.49M |
| September 23, 2024 | -68.65M |
| September 20, 2024 | -65.32M |
| September 19, 2024 | -62.00M |
| September 18, 2024 | -49.28M |
| September 17, 2024 | -48.54M |
| September 16, 2024 | -49.09M |
| September 13, 2024 | -47.23M |
| September 12, 2024 | -49.69M |
| September 11, 2024 | -50.43M |
| September 10, 2024 | -50.46M |
| September 09, 2024 | -32.44M |
| September 06, 2024 | -54.55M |
| September 05, 2024 | -56.37M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-138.82M
Minimum
May 06 2022
1.178B
Maximum
Dec 23 2020
129.27M
Average
-51.90M
Median
Aug 07 2023
Enterprise Value Benchmarks
| Haemonetics Corp | 5.535B |
| Pliant Therapeutics Inc | 463.58M |
| CEL-SCI Corp | 38.36M |
| AIM ImmunoTech Inc | 7.900M |
| IGC Pharma Inc | 26.09M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.26M |
| Revenue (Quarterly) | 1.269M |
| Total Expenses (Quarterly) | 21.40M |
| EPS Diluted (Quarterly) | -3.07 |
| Profit Margin (Quarterly) | -1.52K% |
| Earnings Yield | -87.90% |
| Normalized Earnings Yield | -87.90 |